McKesson (MCK, $127.16) To Move Headquarters From California to Texas
McKesson Corp. will be shifting its headquarters from San Francisco to Las Colinas, Texas. The move will be effective April1. The company, which distributes pharmaceutical products and provides healthcare technology, said that it will move 500 employees from San Francisco to elsewhere around the country and would retain 1,400 jobs in California.
“We are excited to strengthen our presence in Texas and make Las Colinas our official global headquarters,” said John Hammergren, CEO of McKesson, in a statement. “Making this move will improve efficiency, collaboration and cost-competitiveness, while providing an exceptional work environment for our employees.” (as reported by San Francisco Chronicle).
McKesson generated revenue of $198 billion last year, the sixth highest among U.S. public companies.
MCK in upward trend: 10-day moving average broke above 50-day moving average on September 12, 2025
The 10-day moving average for MCK crossed bullishly above the 50-day moving average on September 12, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 08, 2025. You may want to consider a long position or call options on MCK as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MCK just turned positive on August 20, 2025. Looking at past instances where MCK's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
MCK moved above its 50-day moving average on September 09, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MCK advanced for three days, in of 381 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for MCK moved out of overbought territory on September 12, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MCK broke above its upper Bollinger Band on September 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MCK entered a downward trend on August 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (8.276). P/E Ratio (28.491) is within average values for comparable stocks, (25.268). Projected Growth (PEG Ratio) (1.141) is also within normal values, averaging (2.534). Dividend Yield (0.004) settles around the average of (0.031) among similar stocks. P/S Ratio (0.239) is also within normal values, averaging (141.667).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MCK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a distributer of pharmaceuticals and provides healthcare software and health information technology services
Industry MedicalDistributors
Advertisement